Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Fineline Cube Jul 17, 2026
Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Fineline Cube Jul 17, 2026
Policy / Regulatory

Shanghai Releases Local Guidelines to Correct Unhealthy Practices in Pharmaceutical Procurement and Medical Services

Fineline Cube Oct 10, 2024

The Shanghai Municipal Health Commission, along with 13 other bureaus, has issued a local adaptation...

Company Drug

InnoCare Pharma Achieves Positive Phase II Results for TYK2 Inhibitor ICP-488 in Psoriasis Treatment

Fineline Cube Oct 10, 2024

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II...

Company Drug

Ascletis Pharma’s ASC40 Earns FDA Breakthrough Therapy Designation for Fibrotic MASH

Fineline Cube Oct 10, 2024

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that ASC40 (denifanstat), a fatty acid synthase...

Company Deals

HitGen Inc. Partners with Ablink Biotech to Develop Antibody-Oligonucleotide Conjugates

Fineline Cube Oct 10, 2024

China-based HitGen Inc. (SHA: 688222) has entered into a partnership with compatriot firm Ablink Biotech...

Company Drug

Sichuan Biokin’s BL-B01D1 Earns Breakthrough Therapy Designation for Esophageal Cancer from China’s CDE

Fineline Cube Oct 10, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its bispecific antibody drug conjugate...

Company Drug

Merck’s Keytruda Meets Primary Endpoint in Phase III Study for Head and Neck Cancer

Fineline Cube Oct 10, 2024

US pharmaceutical giant Merck & Co., Inc. (MRK, NYSE: MRK) has announced that the Phase...

Company Drug

Boehringer Ingelheim’s Survodutide Earns FDA Breakthrough Therapy Designation for MASH Treatment

Fineline Cube Oct 10, 2024

German pharmaceutical company Boehringer Ingelheim has received breakthrough therapy designation (BTD) from the US Food...

Company

Eli Lilly Appoints Thomas J. Fuchs as First Chief AI Officer to Lead AI Initiatives

Fineline Cube Oct 10, 2024

Eli Lilly and Company (NYSE: LLY) has announced the appointment of Thomas J. Fuchs, Dr.sc.,...

Company Deals

Zephyrm Bioscience Limited Files for IPO on Hong Kong Stock Exchange

Fineline Cube Oct 9, 2024

China-based Zephyrm Bioscience Limited, a biopharmaceutical company specializing in the development of novel pluripotent stem...

Company Drug

Pfizer Halts Development of Sisunatovir, an RSV Antiviral, After Phase II/III Trials

Fineline Cube Oct 9, 2024

U.S. pharmaceutical giant Pfizer (NYSE: PFE) has decided to discontinue the development of sisunatovir, an...

Company Drug

Biogen’s China Unit Gets Conditional NMPA Nod for Qalsody (Tofersen) in ALS Treatment

Fineline Cube Oct 9, 2024

Biogen (NASDAQ: BIIB)’s Chinese subsidiary has announced that it has received conditional approval from the...

Company Drug

Joincare Pharmaceutical Secures NMPA Approval for Triptorelin Microspheres to Treat Endometriosis

Fineline Cube Oct 9, 2024

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...

Company Drug

CSPC Pharmaceutical Secures NMPA Approval for Omalizumab Biosimilar

Fineline Cube Oct 9, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received marketing approval...

Company Deals

Ningbo Menovo Pharmaceutical Partners with Nanjing Huawe Medicine for High-End Product Development

Fineline Cube Oct 9, 2024

Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing...

Company Drug

CSPC Pharmaceutical’s ADC CPO301 Earns Second Fast-Track Designation in the US for NSCLC Treatment

Fineline Cube Oct 9, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...

Company Deals Drug

Bio-Thera Solutions Ltd Strikes Licensing Deal with Gedeon Richter for BAT1706 Biosimilar

Fineline Cube Oct 9, 2024

Guangzhou-based Bio-Thera Solutions Ltd has announced a licensing agreement with Hungary’s Gedeon Richter Plc for...

Company Drug

Jiangsu Aidea Pharmaceutical Secures NMPA Approval for Expanded Indication of Fubangde in HIV Treatment

Fineline Cube Oct 9, 2024

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...

Company Drug

Ascentage Pharma Receives Approval for Two Phase III Trials of APG-2449 in NSCLC

Fineline Cube Oct 9, 2024

China-based biopharmaceutical company Ascentage Pharma (HKG: 6855) has announced that it has received approval from...

Company Medical Device

MicroPort Endovascular MedTech’s Fiber Wool Plug Spring Coil Gains NMPA Marketing Approval

Fineline Cube Oct 9, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has received marketing approval from the National...

Policy / Regulatory

NMPA Expands Generic Quality Consistency Evaluation with 83rd Batch of Reference Drugs

Fineline Cube Oct 9, 2024

The National Medical Products Administration (NMPA) in China has announced the release of the 83rd...

Posts pagination

1 … 318 319 320 … 696

Recent updates

  • CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer
  • CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma
  • Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline
  • Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
  • Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Company

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.